Spinal muscular atrophy is a neurodegenerative disease that requires multidisciplinary medical care. Recent progress in the understanding of molecular pathogenesis of spinal muscular atrophy and advances in medical technology have not been matched by similar developments in the care for spinal muscular atrophy patients. Variations in medical practice coupled with differences in family resources and values have resulted in variable clinical outcomes that are likely to compromise valid measure of treatment effects during clinical trials. The International Standard of Care Committee for Spinal Muscular Atrophy was formed in 2005, with a goal of establishing practice guidelines for clinical care of these patients. The 12 core committee members worked with more than 60 spinal muscular atrophy experts in the field through conference calls, e-mail communications, a Delphi survey, and 2 in-person meetings to achieve consensus on 5 care areas: diagnostic/new interventions, pulmonary, gastrointestinal/nutrition, orthopedics/rehabilitation, and palliative care. Consensus was achieved on several topics related to common medical problems in spinal muscular atrophy, diagnostic strategies, recommendations for assessment and monitoring, and therapeutic interventions in each care area. A consensus statement was drafted to address the 5 care areas according to 3 functional levels of the patients: nonsitter, sitter, and walker. The committee also identified several medical practices lacking consensus and warranting further investigation. It is the authors' intention that this document be used as a guideline, not as a practice standard for their care. A practice standard for spinal muscular atrophy is urgently needed to help with the multidisciplinary care of these patients.
Introduction: Dystrophinopathy is a rare, severe muscle disorder, and nonsense mutations are found in 13% of cases. Ataluren was developed to enable ribosomal readthrough of premature stop codons in nonsense mutation (nm) genetic disorders. Methods: Randomized, double-blind, placebo-controlled study; males ≥5 years with nm-dystrophinopathy received study drug orally 3 times daily, ataluren 10, 10, 20 mg/kg (N = 57); ataluren 20, 20, 40 mg/kg (N = 60); or placebo (N = 57) for 48 weeks. The primary endpoint was change in 6-Minute Walk Distance (6MWD) at Week 48. Results: Ataluren was generally well tolerated. The primary endpoint favored ataluren 10, 10, 20 mg/kg versus placebo; the week 48 6MWD Δ = 31.3 meters, post hoc P = 0.056. Secondary endpoints (timed function tests) showed meaningful differences between ataluren 10, 10, 20 mg/kg, and placebo. Conclusions: As the first investigational new drug targeting the underlying cause of nm-dystrophinopathy, ataluren offers promise as a treatment for this orphan genetic disorder with high unmet medical need. Muscle Nerve
50: 477–487, 2014
Purpose:To analyze T2 maps of pelvic and thigh muscles in Duchenne muscular dystrophy (DMD), to identify the most severely affected muscle, and to correlate the T2 of muscle with the grade of fatty infi ltration at nonquantitative magnetic resonance (MR) imaging and results of clinical assessment .
Materials and Methods:This prospective study was HIPAA compliant and was approved by the institutional review board; written consent was obtained from all participants' parents or guardians. Thirty-four boys with DMD (mean age, 8.4 years) were evaluated clinically (age, clinical function score, timed Gower score, time to run 30 feet, and serum creatine kinase [CK] level) and with nonquantitative MR imaging and axial T2 mapping from the iliac crest to the mid thigh. The T2 maps and mean T2 of 18 muscles in the pelvis and thighs were analyzed to identify the most severely involved muscle. The amount of fatty infi ltration was assigned a grade of zero to four for all pelvic and thigh muscles by using T1-weighted nonquantitative MR images. The Spearman correlation coeffi cients model was used to correlate the mean T2, nonquantitative MR imaging score and clinical assessments.
Results:The gluteus maximus muscle had the highest T2. The mean T2 for this muscle showed a signifi cant correlation with the nonquantitative MR imaging score for fatty infi ltration ( P , .001) and with all clinical assessments except CK level.
Conclusion:Gluteus maximus muscles are most severely affected in patients with DMD. The T2 of the gluteus maximus muscle can be used as a quantitative and objective measure of disease severity.q RSNA, 2010
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.